1. Home
  2. FRD vs ACOG Comparison

FRD vs ACOG Comparison

Compare FRD & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Friedman Industries Inc.

FRD

Friedman Industries Inc.

HOLD

Current Price

$32.39

Market Cap

134.3M

Sector

Industrials

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$8.10

Market Cap

110.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRD
ACOG
Founded
1965
2000
Country
United States
Canada
Employees
N/A
57
Industry
Steel/Iron Ore
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
134.3M
110.4M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
FRD
ACOG
Price
$32.39
$8.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
101.4K
39.9K
Earning Date
06-11-2026
05-14-2026
Dividend Yield
0.79%
N/A
EPS Growth
N/A
N/A
EPS
1.46
N/A
Revenue
$121,157,278.00
N/A
Revenue This Year
N/A
$139.22
Revenue Next Year
N/A
$134.48
P/E Ratio
$22.96
N/A
Revenue Growth
55.82
N/A
52 Week Low
$14.52
$4.50
52 Week High
$37.97
$10.88

Technical Indicators

Market Signals
Indicator
FRD
ACOG
Relative Strength Index (RSI) 56.24 78.57
Support Level $17.90 $5.27
Resistance Level $37.97 N/A
Average True Range (ATR) 2.62 0.57
MACD -0.55 0.17
Stochastic Oscillator 23.70 95.34

Price Performance

Historical Comparison
FRD
ACOG

About FRD Friedman Industries Inc.

Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: